Why the study?
Does low-concentration aspirin protect human coronary artery endothelial cells against atherogenic electronegative LDL (L5)?
Does low-concentration aspirin protect human coronary artery endothelial cells against atherogenic electronegative LDL (L5)?
Aspirin exhibits a novel cytoprotective role against myocardial infarction by epigenetically preventing atherogenic LDL-induced endothelial dysfunction.
Answers are grounded in this paper and cite their sources.
Does not support changing aspirin use; hypothesis-generating for epigenetic endothelial protection in CAD.
Our results show that L5 levels are significantly increased in STEMI patients. Furthermore, L5 impairs HCAEC function through CpG methylation of the FGF2 promoter, which is suppressed in the presence of low-concentration aspirin. Our results provide evidence of a novel mechanism of aspirin in the prevention of MI.
No takes yet. Share an insight, caveat, or question.
Chang et al. (2013) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: